Anti-cd28 antibody for potentiating cytolytic activity of lymphocytes
CA 2034769 A1 · Owner: Oncogen Limited Partnership · Inventors: Ledbetter, Jeffrey A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The development of cytolytic activity of lymphocytes can be potentiated by contacting the lymphocytes with antibody reactive with CD28 receptor such as 9.3 monoclonal antibody. The cytolytic activity thus potentiated is CD3 heteroconjugate-independent since targeting with a CD3 anti-target compound is not required. The development of cytolytic activity can be further potentiated by also contacting the lymphocytes with antibody reactive with anti-CD2 antibody or immobilized antibody to the CD3 receptor or by also, contacting the lymphocytes with interleukin-2. The CD28 receptor may be aggregated on the surface of the lymphocytes, as by crosslinking the antibody reactive to it on the surface …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 23, 1991. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 23, 2011.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 23, 2013.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.